Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: Last status

Indian Journal of Clinical Biochemistry

Volumn 29, Issue 3, 2014, Pages 333-338

  Fatemeh, Dashti Rahmat Abadi ^a   Ebrahimi Shahmabadi, Hasan ^b   Abedi, Anita ^a   Alavi, Seyed Ebrahim ^b   Movahedi, Fatemeh ^b   Koohi Moftakhari Esfahani, Maedeh ^b   Zadeh Mehrizi, Tahereh ^c   Akbarzadeh, Azim ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carboplatinum; Cisplatinum; Drug delivery; Emulsion polymerization; Polybutylcyanoacrylate

Indexed keywords

CARBOPLATIN; CISPLATIN; ENBUCRILATE; NANOPARTICLE; POLY(BUTYL 2 CYANOACRYLATE); UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; EMULSION POLYMERIZATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; NANOTECHNOLOGY; POLYMERIZATION; SPECTROPHOTOMETRY; SURVIVAL RATE;

EID: 84904756224     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-013-0364-6     Document Type: Article

References (36)

1. Ho YP, Au-Yeung SC, To KK. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev. 2003;23:633-55. (Pubitemid 37038095)
2. Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat. 2004;7:227-32. (Pubitemid 39469095)
3. Avichezer D, Schechter B, Arnon R. Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes of polycarboxylates-effect on human ovarian carcinoma. React Funct Polym. 1998;36:59-69. (Pubitemid 128391560)
4. Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R. HPMA copolymer platinates as novel antitumor agents: in vitro, properties, pharmacokinetics and antitumor activity in vivo. Eur J Cancer. 1999;35:994-1002. (Pubitemid 29277137)
5. Newman MS, Golbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatinum encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43:1-7. (Pubitemid 29048341)
6. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs. 1999;10:767-76. (Pubitemid 30015678)
7. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. Cisplatinum-loaded polymer-metal complex micelle with time modulated decaying property as a novel drug delivery system. Pharm Res. 2001;18:1035-41. (Pubitemid 32799952)
8. Ferruti P, Ranucci E, Trotta F, Gianasi E, Evagorou EG, Wasil M, et al. Synthesis, characterization and antitumor activity of platinum II complexes of novel functionalised poly(amidoamine) s. Macromol Chem Phys. 1999;200:1644-54. (Pubitemid 129696302)
9. Xu P, Van Kirk EA, Li S, Murdoch WJ, Ren J, Hussain MD, et al. Highly stable core-surface-crosslinked nanoparticles as cisplatinum carriers for cancer chemotherapy. Colloids Surf B Biointerfaces. 2006;48:50-7.
10. Hirai M, Minematsu H, Hiramatsu Y, Kitagawa H, Otani T, Iwashita S, et al. Novel and simple loading procedure of cisplatinum into liposomes and targeting tumor endothelial cells. Int J Pharm. 2010;391:274-83.
11. Beck PH, Kreuter J, Muller EG, Schatton W. Improved peroral delivery of avarol with polybutyl cyanoacrylate nanoparticles. Eur J Pharm Biopharm. 1994;40:134-7. (Pubitemid 24217258)
12. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol. 1979;31:331-2. (Pubitemid 9207599)
13. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674:171-4.
14. Schroeder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgetic effects of i.v. dalargin injections. Brain Res. 1996;710:121-4. (Pubitemid 26082045)
15. El-Egakey MA, Bentele V, Kreuter J. Molecular weights of polycyanoacrylate nanoparticles. Int J Pharm. 1983;13:349-52. (Pubitemid 13191935)
16. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacokinetics and biodistribution of a biodegradable drug-carrier. Int J Pharm. 1983;15:335-45.
17. Douglas SJ, Davis SS, Illum L. Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits. Int J Pharm. 1986;34:145-52.
18. Sommerfeld P, Schroeder U, Sabel BA. Long-term stability of PBCA nanoparticle suspensions suggests clinical usefulness. Int J Pharm. 1997;155:201-7. (Pubitemid 27380406)
19. Gaspar R, Preat V, Roland M. Nanoparticles of polyisohexyl cyanoacrylate (PIHCA) as carriers of primaquine: formulation, physico-chemical characterization and acute toxicity. Int J Pharm. 1991;68:111-9.
20. Marchal-Heussler I, Maincent P, Hoffman M, Spittler J, Couvreur P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutyl cyanoacrylate nanoparticle preparations. Int J Pharm. 1990;58:115-22. (Pubitemid 20042451)
21. Verdun C, Couvreur P, Vranckx H, Lenaerts V, Roland M. Development of a nanoparticle controlled-release formulation for human use. J Cont Rel. 1986;3:205-10. (Pubitemid 16168151)
22. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999;16:1564-9. (Pubitemid 29510553)
23. Zarei M, Norouzian D, Chiani M, Ebrahimi H, Mohammadi M, Akbarzadeh A. Advantages of paclitaxel-loaded nano niosomes to nanoliposomal formulation: an in vitro study. Int J Life Sci Bt & Pharm Res. 2013;2:335-42.
24. Litterst CL, LeRoy AF, Guarino AM. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep. 1979;63: 1485-92. (Pubitemid 10167743)
25. Bofetta P, Fichtinger-Schepman AMJ, Weiderpass E, Andijkknijnenburg HCM, Stoter G, Vanoosterom AT, et al. Cisplatinum-DNA adducts and protein-bound platinum in blood of testicular cancer patients. Anticancer Drugs. 1998;9:125-9. (Pubitemid 28080632)
26. Ogilvie GK, Fettman MJ, Jameson VJ, Walters LM, La¡erty MH, Cooper MF, et al. Evaluation of a one-hour saline diuresis protocol for administration of cisplatinum to dogs. Am J Vet Res. 1992;53:1666-9.
27. Yan X, Gemeinhart RA. Cisplatinum delivery from poly (acrylic acid-co-methyl methacrylate) microparticles. J Control Release. 2005;106:198-208. (Pubitemid 41149078)
28. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631-51. (Pubitemid 35247520)
29. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Controlled Release. 2003;93:151-60. (Pubitemid 37421357)
30. Peracchia MT, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, Desmaële D, et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials. 1999;20:1269-75. (Pubitemid 29281378)
31. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006;310:213-9. (Pubitemid 43287986)
32. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated polybutylcyanoacrylate nanoparticles: revisiting the role of surfactants. J Controlled Release. 2007;117:51-8. (Pubitemid 46164866)
33. Vauthier C, Labarre D, Ponchel G. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target. 2007;15(10):641-63. (Pubitemid 350201318)
34. Egea MA, Gamisans F, Valero J, Garcia ME, Garcia ML. Entrapment of cisplatinum into biodegradable polyalkylcyanoacrylate nanoparticles. Farmaco. 1994;49:211-7. (Pubitemid 24165639)
35. Doz F, Berens ME, Dougherty DV, Rosenblum ML. Comparison of the cytotoxic activities of cisplatinum and carboplatinum against glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol. 1991;11:27-35.
36. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58:97-110. (Pubitemid 351521865)